menu search

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 – Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum Raised Gross Proceeds of $32.5 Million in February 2023 in an Underwritten Offering VP-315 Advanced into Part 2 of Phase 2 Trial in Basal Cell Carcinoma WEST CHESTER, Pa., May […] The post Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results appeared first on ForexTV... Read More
Posted: May 9 2023, 11:30
Author Name: forextv
Views: 102037

Search within

Pages Search Results: